RFK Jr: Recruit Dr. Vinay Prasad to Run an RCT of the Routine Vaccine Schedule

In modern health-policy debates, there’s one phrase that gets tossed around like a “get out of arguments free” card:
“Do a randomized controlled trial.” It’s the scientific equivalent of telling a contractor,
“Just build the house… but, you know, make it perfect, fast, and cheap.”

Recently, that instinct has collided with the nation’s loudest vaccine controversies. Critics of the current
U.S. routine childhood immunization schedule want “gold standard” proof that the entire schedule is safe.
Supporters point out we already have mountains of evidence from clinical trials, decades of real-world surveillance,
and independent reviews. Into that mess comes a provocative dare that’s been circulating in commentary:
if RFK Jr. wants an RCT of the routine schedule, recruit Dr. Vinay Prasad to run it.

It’s a headline-ready ideadramatic, tidy, and tailor-made for social media. But like most tidy ideas in public
health, the moment you try to actually build it, you run into three stubborn realities: ethics,
feasibility, and what “an RCT” can and can’t prove.

What People Mean When They Say “Run an RCT of the Routine Vaccine Schedule”

An RCT is designed to answer a specific question by randomly assigning people to an intervention or a comparison.
That randomization reduces bias and helps isolate cause and effect. In drug development, that often means:
Drug A versus placebo (or Drug A versus an existing treatment).

But the phrase “RCT of the routine vaccine schedule” isn’t one questionit’s a whole stack of questions wearing
one trench coat:

• Is the schedule safe overall?
• Is giving multiple vaccines at one visit riskier than spacing them out?
• Are there long-term effects that weren’t detected in pre-licensure trials?
• Do different countries’ schedules lead to better outcomes?
• Are there rare harms that only show up in huge populations?

Those questions matter. But they don’t all have the same best study design. The biggest misconception is that if
something is important, the only “real” way to study it is a single mega-RCT that settles everything forever.
Science doesn’t work like a movie courtroom scene. It works like a slow, frustrating group project with footnotes.

Why Dr. Vinay Prasad’s Name Keeps Coming Up

Dr. Vinay Prasad is known for blunt commentary about evidence standards, medical reversals, and policy decisions.
He has arguedoften loudlythat medicine should demand better proof before making sweeping recommendations, and he
has discussed the idea of using cluster randomized trials (randomizing groups like counties or states)
to compare different approaches to vaccination schedules and other policies.

In other words, if you’re looking for someone who likes RCTs the way some people like hot sauce (on everything,
including breakfast cereal), he’s a predictable pick for the conversation.

The “recruit Prasad” framing is also politically legible: it suggests a kind of high-stakes scientific showdown.
But the real question isn’t “Could Prasad design a trial?” It’s:
Could anyone run an ethically acceptable, logistically workable, scientifically meaningful RCT of routine childhood vaccination as currently practiced?

The Ethical Wall: You Can’t Randomize Children Into Avoidable Risk

Here’s the part that turns the headline into a headache. A traditional RCT of the routine schedule would require
something like:

• Group A follows the recommended schedule.
• Group B follows an alternative scheduleor receives fewer vaccinesor delays vaccines.

If the alternative meaningfully reduces protection against serious diseases, you’ve just created a study where a
group of kids is intentionally left more vulnerable to harm. That isn’t a spicy debate point; it’s a problem for
institutional review boards (IRBs), pediatricians, and parents who do not want their child assigned to
“more risk, please.”

Modern vaccine trials already wrestle with these ethical limits. Once an effective vaccine exists, withholding it
just to create a clean placebo comparison is often considered unethical. That’s why many vaccine trials use an
existing vaccine comparator rather than salinerigorous science, but without unnecessary exposure to preventable
disease.

This is not a new argument invented for today’s political weather. It’s a core principle in clinical research ethics:
when there is an established effective intervention, you need a strong justification to deprive participants of it.

The Feasibility Wall: The Trial You Want Is the Trial You Can’t Run

Let’s pretend, for a moment, the ethics board doesn’t immediately faint into its coffee. You still face brutal
practicality:

1) The sample size would be enormous

If your goal is to detect rare adverse events, you need very large populations. If your goal is to detect small
differences in long-term outcomes, you need even larger populations plus years of follow-up.

2) Outcomes are messy

What’s the endpoint? Infection rates? Hospitalizations? All-cause outcomes? Specific diagnoses? Rare events?
Childhood vaccination involves multiple diseases with different baselines, different seasons, and different risk
profiles. The schedule isn’t one exposure; it’s many exposures over time.

3) Compliance would collapse

Even if you randomized counties, families can move. Clinicians can deviate. Parents can opt out. Local outbreaks
change behavior. In a politicized environment, half the trial would be litigated on cable news before the first
infant wellness visit.

In short: “Just do an RCT” sounds like a power move. In practice, it’s often a way to demand an impossible study
and then claim that anything short of it “doesn’t count.”

So… Is the Routine Schedule “Unstudied”? No. That’s Not How Vaccine Evidence Works.

A key fact that gets lost in the shouting: routine childhood vaccines are not introduced by vibes. Before licensure,
vaccines typically go through phased clinical testing that evaluates safety and immune response, and often efficacy.
After licensure, safety monitoring continuesbecause rare events might only be detectable when millions of doses are used.

The U.S. has multiple layers of vaccine safety surveillance, including:

• VAERS, a national reporting system that can flag potential safety signals for follow-up.
• Vaccine Safety Datalink (VSD), which uses electronic health record data for active monitoring and studies.
• PRISM/BEST and other FDA-linked systems that analyze large claims databases to detect signals.
• Clinical networks that investigate complex cases and refine guidance.

Think of it like aviation safety. You don’t “prove planes are safe” with one gigantic coin-flip experiment where
some passengers get parachutes and some don’t. You combine engineering standards, controlled testing, surveillance,
incident investigation, and iterative improvements. Vaccine safety is built the same way: layers, not one magic trial.

What Major Reviews Have Said About the Schedule

Independent scientific reviews have examined concerns about the recommended schedule as a whole, including questions
about timing and multiple vaccines. One influential U.S. review concluded it found no evidence of major safety
concerns associated with adherence to the childhood immunization schedulewhile also emphasizing that ongoing
research should continue and that certain questions are harder to answer than others.

That last clause matters. “No major safety concerns found” is not “we’re done studying forever.” It’s “we have not
seen credible signals that the schedule is broadly harmful, and we should keep improving research methods and monitoring.”

Why the “Whole Schedule RCT” Is a Bad Fitand What Better Research Would Look Like

If the goal is to strengthen confidence and answer legitimate scientific questions, there are research approaches that
are far more realistic than randomizing children into lower protection.

1) Study specific, actionable questions

Instead of “Is the entire schedule safe?” ask questions that can be tested without ethical gymnastics:

• Do certain co-administration combinations increase specific short-term reactions compared with spacing within acceptable windows?
• Are there subgroups (by age, underlying conditions, prior infection) where risk-benefit differs for specific vaccines or boosters?
• Does changing timing by a small interval preserve protection while improving tolerability?

2) Use pragmatic trials where no one is denied standard protection

Randomization can still be used ethically, but the intervention might be:

• Different reminder systems (text, call, portal prompts) to improve on-time vaccination.
• Different clinic workflows for co-administration counseling.
• Different transparency tools (public dashboards, clearer consent materials) to measure trust and uptake.

These trials won’t satisfy people who want a dramatic “vaccines versus no vaccines” showdown. But they would produce
results that actually improve systems and outcomeswithout gambling with children’s health.

3) Expand active safety surveillance and publish it in plain English

A lot of the distrust problem isn’t “lack of data.” It’s “people don’t feel they can see or understand the data.”
Investing in better, faster, more transparent safety analysesplus clear communication about what is known, what is
uncertain, and how signals are investigatedcan do more for public trust than a moonshot RCT that never enrolls.

4) Compare schedules using careful observational methods

If the question is “Do countries with different schedules have different outcomes?” you can analyze real-world data:
hospitalization rates, outbreak patterns, coverage levels, and confounders like health access and reporting systems.
It’s not as clean as randomization, but it’s doableand it reflects how public health decisions are often evaluated
in reality.

If RFK Jr. Really Wanted “Gold Standard Science,” Here’s the Catch

The catch is that “gold standard science” is not synonymous with “one huge RCT.” The gold standard is:

• Well-defined questions
• Methods that fit the question
• Ethical protections
• Independent oversight
• Transparency about uncertainty
• Willingness to update recommendations based on credible signals

If a public official demands an impossible trial, it can become a rhetorical trap:
“Since you can’t do my preferred study, I get to claim the evidence is weak.” That isn’t scientific rigor.
It’s a debate tactic dressed up as a lab coat.

So Where Does the “Recruit Prasad” Idea Land?

As a headline, it’s clever. As a policy proposal, it’s a stress test:

• If it means a true schedule-versus-no-schedule experiment, it’s ethically indefensible and likely infeasible.
• If it means cluster trials comparing modest schedule variations that preserve protection, it could be discussedbut it’s not the dramatic “settle it all” event people imagine.
• If it means tightening evidence standards for specific vaccine decisions (like boosters in low-risk groups), that’s a different debateone that still must balance speed, feasibility, and protection.

The real value of the idea might be that it forces everyone to stop speaking in slogans and start speaking in study designs.
“RCT” is not a spell you cast. It’s a blueprint you have to buildand the building has to pass an ethics inspection.

Experiences From the Front Lines (and Why This Debate Feels So Personal)

If you want to understand why “RCT the routine schedule” detonates emotions, don’t start with Twitter. Start with
the ordinary places where vaccination actually happens: pediatric offices, public health clinics, hospital wards,
and family kitchens at 11 p.m. when a toddler finally falls asleep.

The pediatrician’s experience: Many pediatric clinicians describe vaccine visits as part medicine,
part counseling, part diplomacy. The appointment isn’t just shots; it’s a conversation about risk in a world where
“risk” is misunderstood. Some parents want a slow, careful explanation. Others are already overwhelmed by childcare,
bills, and the fact that their child ate a crayon yesterday and seems fine. When a public figure frames the schedule
as suspicious or “untested,” pediatricians can feel like they’re arguing against a foghorn with a paper fan.

The parent’s experience: Parents don’t experience “the schedule” as an abstract policy. They experience
it as a tiny human who might spike a fever, fuss all night, or cry in the car seat afterward. They also experience it
as fearfear of disease, fear of side effects, fear of making the wrong call and being blamed forever. In that emotional
context, “Do an RCT” sounds comforting because it promises certainty. But the hard truth is that certainty is rare in
biology. What parents usually need is honesty: what we know, what we don’t, how we monitor safety, and what happens when
a legitimate signal appears.

The vaccine safety scientist’s experience: People who work in safety surveillance often talk about the
grind: sifting signals from noise, checking coding artifacts, verifying diagnoses, and running analyses that the public
will never seeuntil something triggers a headline. They know VAERS reports can be incomplete or misleading without follow-up,
so they treat it as a starting point, not an ending point. They know observational studies can be biased, so they build
stronger designs within real-world constraints. When critics say “no one is looking,” these scientists tend to respond
with a tired kind of disbelief: we have been looking, constantly, for decades.

The IRB member’s experience: Research ethics isn’t about being anti-science; it’s about preventing
science from becoming cruelty in a lab coat. An IRB reviewer hearing “randomize babies to fewer routine vaccines”
doesn’t picture an elegant methodology. They picture preventable infections, avoidable hospitalizations, and the
moral injury of knowingly assigning risk. That doesn’t mean all research is blockedfar from it. It means the
research must be designed so that participants aren’t denied established protection without compelling justification.

The public health communicator’s experience: There’s a specific frustration that comes with the phrase
“just run an RCT.” Communicators know that if they say “we already have strong evidence,” some audiences hear
“we don’t want to study it.” If they say “we can’t ethically do that trial,” some audiences hear
“we’re hiding something.” It’s a lose-lose framing. The only way out is to change the question from
“Why won’t you run my dream trial?” to “Which studies best answer which concernsand how will results be shared transparently?”

In real life, the vaccine schedule isn’t a philosophical debate club topic. It’s a set of decisions that shape
whether outbreaks happen, whether vulnerable kids are protected, and whether parents can trust the institutions
that claim to have their child’s best interest in mind. If leaders truly want to rebuild trust, the most effective
“experiment” may not be randomizing children to different vaccine exposures. It may be randomizing the system to
better transparency: faster publication of safety monitoring, clearer conflict-of-interest disclosures, open methods,
and a communication style that respects the public’s intelligence without pretending science is ever perfectly simple.

Because here’s the quiet truth: when people ask for an RCT of the entire schedule, they are often asking for a feeling,
not just a statistic. They want reassurance that someone is taking their fear seriously. The best response is not to
mock the fear, or to promise an impossible mega-trial. It’s to show the workclearly, repeatedly, and with receipts.